UBS Maintains Buy on AdaptHealth, Lowers Price Target to $14
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Kevin Caliendo maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $15 to $14.
UBS analyst Kevin Caliendo maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $15 to $14.